Cytotoxicity assessment of nanoliposomal Paclitaxel and nanoliposomal Hydroxyurea in MCF-7 cells

Nanotechnology has revolutionized diagnosis and treatment of cancers. Breast cancer is oneof the most prevalent cancers among women. Paclitaxel and hydroxyurea are important drugsin treatment of breast cancer but their use is limited due to a series of significant side effects.On the other hand, nanoliposomes are widely used as nanocarriers for targeted drug delivery.In this study, cytotoxic effects of nanoliposomal hydroxyurea and nanoliposomal Paclitaxelwere investigated. Liposomes were prepared using reversed phase evaporation.Cytotoxicity ofliposomal formulations of the drugs was determined using Methylthiazolyldiphenyl-tetrazoliumbromide (MTT) method. Results showed an IC50 level of 86.25 μl/ml for nanoliposomalHydroxyureaand and 43.78 μl/ml for nanoliposomal Paclitaxel. In general, it can be concludedthat that cytotoxicity of nanoliposomal drugs are higher than that of standard formulations.